Researchers Describe Aggressive Breast Cancer Molecular Mechanism
|
By LabMedica International staff writers Posted on 11 Nov 2016 |

Image: The structural model of the SIRT2 protein (Photo courtesy of Wikimedia Commons).
Cancer researchers have found that SIRT2, a member of the sirtuin family of enzymes, stabilizes Slug, a transcription factor that promotes the development, growth, and spread of basal-like breast cancer.
Overabundance of Slug protein is common in human cancer and represents an important determinant underlying the aggressiveness of basal-like breast cancer (BLBC). Despite its importance, this transcription factor is rarely mutated in BLBC, and the mechanism of its deregulation in cancer remains unknown.
To better understand the link between Slug and BLBC, investigators at Tufts University School of Medicine (Boston, MA, USA) screened BLBC cultures for factors that would stabilize Slug activity.
They reported in the October 25, 2016, online edition of the journal Cell Reports that Slug underwent acetylation-dependent protein degradation and identified the deacetylase SIRT2 as a key mediator of this post-translational mechanism. SIRT2 inhibition rapidly destabilized Slug, whereas SIRT2 overexpression extended Slug stability. SIRT2 deacetylated Slug protein at lysine residue K116 to prevent Slug degradation.
SIRT2 was frequently amplified and highly expressed in BLBC. Genetic depletion and pharmacological inactivation of SIRT2 in BLBC cells reversed Slug stabilization, caused the loss of clinically relevant pathological features of BLBC, and inhibited tumor growth. Without SIRT2, tumor cells had a more than 60% reduction in invasive capacity compared to normal basal-like tumor cells. SIRT2-depleted cells also had significantly decreased capacity for growth and self-renewal. This diminished malignancy could be reversed by artificially introducing Slug protein back into cells.
"Breast cancer is not one disease, and of the several distinct subtypes, basal-like breast cancer represents the most aggressive form. By targeting a master transcription factor regulator in basal-like cells, we were able to reduce malignant behaviors," said senior author Dr. Charlotte Kuperwasser, professor of developmental, molecular, and chemical biology at Tufts University School of Medicine. "Our findings now provide a molecular rationale for new approaches to help improve the poor clinical outcomes currently associated with these cancers."
"Cancer cells find sophisticated ways to regulate essential proteins they need for their survival and growth. The transcriptional factor Slug is one such protein and is often tightly regulated in both normal and cancer cells. While we have found that SIRT2 plays an important role in prolonging Slug expression, it is too soon to know whether targeting SIRT2 will be sufficient to abolish Slug entirely in cancer cells and therefore lead to tumor regression," said Dr. Kuperwasser. "A significant amount of work remains to be done before we can verify if targeting SIRT2 can be an Achilles' heel for treating basal-like breast cancers."
Related Links:
Tufts University School of Medicine
Overabundance of Slug protein is common in human cancer and represents an important determinant underlying the aggressiveness of basal-like breast cancer (BLBC). Despite its importance, this transcription factor is rarely mutated in BLBC, and the mechanism of its deregulation in cancer remains unknown.
To better understand the link between Slug and BLBC, investigators at Tufts University School of Medicine (Boston, MA, USA) screened BLBC cultures for factors that would stabilize Slug activity.
They reported in the October 25, 2016, online edition of the journal Cell Reports that Slug underwent acetylation-dependent protein degradation and identified the deacetylase SIRT2 as a key mediator of this post-translational mechanism. SIRT2 inhibition rapidly destabilized Slug, whereas SIRT2 overexpression extended Slug stability. SIRT2 deacetylated Slug protein at lysine residue K116 to prevent Slug degradation.
SIRT2 was frequently amplified and highly expressed in BLBC. Genetic depletion and pharmacological inactivation of SIRT2 in BLBC cells reversed Slug stabilization, caused the loss of clinically relevant pathological features of BLBC, and inhibited tumor growth. Without SIRT2, tumor cells had a more than 60% reduction in invasive capacity compared to normal basal-like tumor cells. SIRT2-depleted cells also had significantly decreased capacity for growth and self-renewal. This diminished malignancy could be reversed by artificially introducing Slug protein back into cells.
"Breast cancer is not one disease, and of the several distinct subtypes, basal-like breast cancer represents the most aggressive form. By targeting a master transcription factor regulator in basal-like cells, we were able to reduce malignant behaviors," said senior author Dr. Charlotte Kuperwasser, professor of developmental, molecular, and chemical biology at Tufts University School of Medicine. "Our findings now provide a molecular rationale for new approaches to help improve the poor clinical outcomes currently associated with these cancers."
"Cancer cells find sophisticated ways to regulate essential proteins they need for their survival and growth. The transcriptional factor Slug is one such protein and is often tightly regulated in both normal and cancer cells. While we have found that SIRT2 plays an important role in prolonging Slug expression, it is too soon to know whether targeting SIRT2 will be sufficient to abolish Slug entirely in cancer cells and therefore lead to tumor regression," said Dr. Kuperwasser. "A significant amount of work remains to be done before we can verify if targeting SIRT2 can be an Achilles' heel for treating basal-like breast cancers."
Related Links:
Tufts University School of Medicine
Latest BioResearch News
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
Channels
Clinical Chemistry
view channel
New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
Predicting which patients with early symptomatic Alzheimer’s disease will decline more rapidly remains a key challenge in both research and patient care. Growing interest in tau biology, along with advances... Read more
Routine Blood Markers Predict Heart Failure Risk in Prediabetes
Heart failure prevention relies on finding high-risk adults before symptoms appear, yet effective stratification remains difficult in routine care. Prediabetes affects an estimated 115.2 million U.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Enables Faster Diagnosis of Childhood Cancer in Africa
Burkitt lymphoma is the most common childhood cancer in Africa and progresses rapidly, making fast, accurate diagnosis essential to survival. Although survival can exceed 90% when therapy starts quickly,... Read more
Blood Test Helps Guide Treatment in Older Women with Breast Cancer
Older women with estrogen receptor–positive breast cancer often face difficult decisions about treatment, especially when surgery and radiation can lead to side effects such as scarring, swelling, infection... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read more
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read moreMicrobiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read more
New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
Invasive Candida infections are challenging for healthcare systems, with some strains spreading rapidly in hospitals and showing resistance to multiple antifungal drugs. Candida auris is associated with... Read moreTechnology
view channel
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read more
New Electronic Pipette Enhances Workflows with Touchscreen Control
Manual pipetting remains a routine yet error-prone step that can affect reproducibility and throughput in clinical and research laboratories. Training demands and ergonomic strain also add variability... Read more
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Automated MSI Test Gains IVDR Certification to Guide CRC Therapy
Treatment selection for metastatic colorectal cancer often requires knowledge of a tumor’s microsatellite instability (MSI) status. Timely results can help clinicians decide on immunotherapy options.... Read more








